Showing results (81-90 of 122) with videos related to

Sort By:
Pageof 13
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2015
Thromboelastography in the Management of Coagulopathy Associated With Ebola Virus DiseaseAndrew J Wilson, Daniel S Martin, Victoria Maddox, et al.
Scientific Reports|August 26, 2017
Hypercoagulability progresses to hypocoagulability during evolution of acetaminophen-induced acute liver injury in pigsKarla Chui Luan Lee, Luisa Baker, Susan Mallett, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 19, 2022
Examining patient and professional perspectives in the UK for gene therapy in haemophiliaIone Woollacott, George Morgan, Pratima Chowdary, et al.
Blood Advances|July 15, 2022
Differences in wild-type- and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepanciesJonathan H Foley, Erald Shehu, Anne Riddell, et al.
Research and Practice in Thrombosis and Haemostasis|October 6, 2025
Emicizumab utilization, safety, and outcomes in people with severe hemophilia and no inhibitors: 3-year follow-up. A report from the UK Haemophilia Centre Doctors' OrganisationCaroline Wall, Hua Xiang, Ben Palmer, et al.
European Journal of Haematology|July 11, 2012
History of non-fatal cardiovascular disease in a cohort of Dutch and British patients with haemophiliaDietje E Fransen van de Putte, Kathelijn Fischer, Michael Makris, et al.
Blood Advances|December 8, 2021
Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective studyPaul Van Der Valk, Michael Makris, Kathelijn Fischer, et al.
Thrombosis and Haemostasis|September 8, 2012
Increased prevalence of hypertension in haemophilia patientsDietje E Fransen van de Putte, Kathelijn Fischer, Michael Makris, et al.
Thrombosis and Haemostasis|November 10, 2012
Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patientsDietje E Fransen van de Putte, Kathelijn Fischer, Michael Makris, et al.
Research and Practice in Thrombosis and Haemostasis|April 1, 2024
Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studiesJohnny Mahlangu, Víctor Jiménez-Yuste, Giuliana Ventriglia, et al.
Pageof 13